Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NK cell subsets define sustained remission in rheumatoid arthritis
Carl Coyle, … , Rowann Bowcutt, Esperanza Perucha
Carl Coyle, … , Rowann Bowcutt, Esperanza Perucha
Published October 17, 2024
Citation Information: JCI Insight. 2024;9(23):e182390. https://doi.org/10.1172/jci.insight.182390.
View: Text | PDF
Research Article

NK cell subsets define sustained remission in rheumatoid arthritis

  • Text
  • PDF
Abstract

Rheumatoid arthritis (RA) is an immune-mediated, chronic inflammatory condition. With modern therapeutics and evidence-based management strategies, achieving sustained remission is increasingly common. To prevent complications associated with prolonged use of immunosuppressants, drug tapering or withdrawal is recommended. However, due to the lack of tools that define immunological remission, disease flares are frequent, highlighting the need for a more precision medicine–based approach. Utilizing high-dimensional phenotyping platforms, we set out to define peripheral blood immunological signatures of sustained remission in RA. We identified that CD8+CD57+KIR2DL1+ NK cells are associated with sustained remission. Functional studies uncovered an NK cell subset characterized by normal degranulation responses and reduced proinflammatory cytokine expression, which was elevated in sustained remission. Furthermore, flow cytometric analysis of NK cells from synovial fluid combined with interrogation of a publicly available single-cell RNA-Seq dataset of synovial tissue from active RA identified a deficiency of the phenotypic characteristics associated with this NK cell remission signature. In summary, we have uncovered an immune signature of RA remission associated with compositional changes in NK cell phenotype and function that has implications for understanding the effect of sustained remission on host immunity and distinct features that may define operational tolerance in RA.

Authors

Carl Coyle, Margaret Ma, Yann Abraham, Christopher B. Mahony, Kathryn Steel, Catherine Simpson, Nadia Guerra, Adam P. Croft, Stephen Rapecki, Andrew Cope, Rowann Bowcutt, Esperanza Perucha

×

Figure 6

Phenotypic features associated with sustained remission are reduced on NK cells from the joint of active RA.

Options: View larger image (or click on image) Download as PowerPoint
Phenotypic features associated with sustained remission are reduced on N...
(A) Expression of CD56 and CD16 defines CD56brightCD16– and CD56dimCD16+ subsets between paired peripheral blood (PB) and synovial fluid (SF) (n = 6). (B) The proportion of CD56bright NK cells between PB and SF. (C–E) The expression of CD57, NKG2A, and KIR2DL1 across CD56dim and CD56bright NK cells in PB and CD56bright NK cells in SF. (F) UMAP plot demonstrating 8 transcriptional NK Cell/ILC clusters derived from single-cell RNA-Seq on synovial tissue from patients with active RA. (G) UMAP feature plot showing the expression of B3GAT1 across CD56bright and CD56dim clusters. (H) Comparison of the proportion of CD56dim NK cells not expressing and expressing B3GAT1 across individual tissue samples (n = 63). (I) Bubble plots demonstrating the percentage of cells expressing genes for specific inhibitory receptors and their expression levels across CD56bright and CD56dim clusters. (J) Comparing the proportion of CD56dim NK cells expressing KLRC1 to cells expressing genes encoding each corresponding KIR. (K and L) The proportion of NK cells expressing KLRC1 versus KIR2DL1 at a greater than or less than 2-fold difference. Whiskers on plots represent minimum to maximum values. All P values were determined using the Mann-Whitney U test (B–E and H), the Kruskal-Wallis test with Dunn’s multiple-test correction (J), and the Wilcoxon matched-pairs signed-rank test (K and L). **P < 0.01, ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts